CureVac walks away from Arcturus’ urea cycle disorder drug, but partnership remains intact

Arcturus Therapeutics had a melodramatic 2018?? the?San Diego biotech?s CEO Joseph Payne was asked to leave for putting his interests before the RNA company, but he fought back with the support of shareholders,?ousted the board that spearheaded his ouster and was reinstated. But under Payne, the drug developer has lost the support of collaborator?CureVac in the development of a drug for the most?common urea cycle disorder?? ornithine transcarbamylase deficiency (OTCD), a life-threatening genetic disease.

Joseph Payne

CureVac and Arcturus